Catalent to divest UK site; Rottendorf, Evonik announce manufacturing builds

Catalent to sell its Nottingham, UK site to Codis; Evonik pledges $100M in Indiana and Rottendorf plans a €100M German campus. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…

Source: Endpoints News